CA127-1030 (TRIDENT-3)

{ "short_title": "CA127-1030 (TRIDENT-3)", "data_mode": "900", "data_mode_number": "000002316", "official_title": "Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naive ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": "NCT06140836", "eudract_number": null, "general_contact_email": "oncostudy@ukdd.de", "general_contact_phone": "+49 351-4587666", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Ziel dieser Studie ist es, die Wirksamkeit und Sicherheit von Repotrectinib und Crizotinib bei Teilnehmern mit lokal fortgeschrittenem oder metastasiertem TKI-naivem ROS1-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) zu untersuchen.", "description_laie_en": "The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naive ROS1-positive non-small cell lung cancer (NSCLC).", "description_expert_de": "Ziel dieser Studie ist es, die Wirksamkeit und Sicherheit von Repotrectinib und Crizotinib bei Teilnehmern mit lokal fortgeschrittenem oder metastasiertem TKI-naivem ROS1-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) zu untersuchen.", "description_expert_en": "The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naive ROS1-positive non-small cell lung cancer (NSCLC).", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 10, "sub_cat_id": 50 }